Annovis Bio - ANVS Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Annovis Bio in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ANVS shares.
View ANVS analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued 12 month price targets for Annovis Bio's shares. Their ANVS share price forecasts range from $40.00 to $40.00. On average, they predict the company's stock price to reach $40.00 in the next twelve months. This suggests a possible upside of 192.0% from the stock's current price.
View analysts price targets for ANVS or view top-rated stocks among Wall Street analysts.

Annovis Bio's stock was trading at $13.43 at the start of the year. Since then, ANVS stock has increased by 2.0% and is now trading at $13.70.
View the best growth stocks for 2023 here.

Annovis Bio saw a increase in short interest during the month of December. As of December 30th, there was short interest totaling 198,300 shares, an increase of 21.9% from the December 15th total of 162,700 shares. Based on an average daily volume of 31,400 shares, the short-interest ratio is currently 6.3 days. Currently, 3.5% of the shares of the company are short sold.
View Annovis Bio's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 1st 2023.
View our ANVS earnings forecast.

Annovis Bio, Inc. (NYSE:ANVS) issued its quarterly earnings results on Tuesday, November, 8th. The company reported ($0.93) earnings per share for the quarter, beating the consensus estimate of ($1.17) by $0.24.

Based on aggregate information from My MarketBeat watchlists, some companies that other Annovis Bio investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), KushCo (KSHB), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Auxly Cannabis Group (CBWTF), Novan (NOVN), Sorrento Therapeutics (SRNE), CNBX Pharmaceuticals (CNBX) and Enerplus (ERF).

(ANVS) raised $10 million in an initial public offering on Wednesday, January 29th 2020. The company issued 1,400,000 shares at a price of $6.00-$8.00 per share. ThinkEquity (a division of Fordham Financial Management, Inc. ) acted as the underwriter for the IPO.

Annovis Bio trades on the New York Stock Exchange (NYSE) under the ticker symbol "ANVS."

Annovis Bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Merit Financial Group LLC (0.53%). Insiders that own company stock include Claudine Bruck, Maria-Luisa Maccecchini and Reid Mccarthy.
View institutional ownership trends.

Shares of ANVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ANVS stock can currently be purchased for approximately $13.70.

Annovis Bio (NYSE:ANVS) has a market capitalization of $111.79 million. The company earns $-14,490,000.00 in net income (profit) each year or ($3.47) on an earnings per share basis.

Annovis Bio's mailing address is 1055 Westlakes Drive Suite 300, Berwyn PA, 19312. The official website for the company is www.annovisbio.com. The company can be reached via phone at 610-727-3913 or via email at joeh@gregoryfca.com.